Transgene's Mid-Year Financial Report: Key Insights Revealed

Overview of Transgene's Financial Progress
TRANSGENE (Paris: TNG) is pleased to share the latest updates regarding its financial performance. The company has officially released its half-year financial report, providing valuable insights as of June 30, 2025.
The report is now accessible to the public, allowing interested stakeholders to understand the company’s financial standing and operational developments during the first half of the fiscal year.
Accessing the Financial Report
The financial document can be found on the official Transgene website under the “Investors/Financial Information” section. This is part of the company's commitment to transparency and keeping its investors informed about financial health and strategic direction.
Components of the Financial Report
This half-year financial report encompasses several key documents that provide an in-depth view of the company’s operations and fiscal activities:
Comprehensive financial statements for the year 2025, illustrating revenue, expenses, and profitability.
A detailed management report summarizing operations and strategic initiatives undertaken during the first half.
The Statutory Auditors’ report which ensures the integrity and accuracy of the financial statements.
A declaration from the responsible party for this report, affirming its reliability.
Contacts for Further Information
If you have any media inquiries or require additional information regarding the report or the company's performance, the designated contacts are available to assist.
Media Inquiries
Caroline Tosch
Corporate and Scientific Communications Manager
Contact: +33 3 68 33 27 38
Email: communication@transgene.fr
Investors & Analysts
Nadège Bartoli
Investor Relations Analyst and Financial Communication Officer
Contact: +33 3 88 27 91 03
Lucie Larguier
Chief Financial Officer
Contact: +33 3 88 27 91 00
Email: investorrelations@transgene.fr
Frequently Asked Questions
What is the significance of the financial report?
The financial report provides transparency regarding Transgene's performance, helping investors assess the company's fiscal health and strategic direction.
Where can I find the financial report?
The report is available on Transgene's official website, specifically in the Investors/Financial Information section.
How often does Transgene release financial reports?
Transgene typically releases financial reports bi-annually, providing updates for the first and second halves of the fiscal year.
Who can I contact for more information?
For media inquiries, reach out to Caroline Tosch. For investor relations, contact Nadège Bartoli or Lucie Larguier.
What documents are included in the half-year report?
The half-year report includes financial statements, a management report, an auditor's report, and a declaration from the responsible party.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.